Leo Pharma elaborates on 2030 strategy after new capital injection

Backed by Nordic Capital, Leo Pharma is now free to power ahead with the strategy that will ideally lead to Leo Pharma becoming a global, leading player in medical dermatology by 2030, according to CEO Catherine Mazzacco.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The reason why Leo Pharma is gaining new capital through divesting parts of its ownership is very specific.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading